Pfenex (PFNX -4.4%) said Theramex, the European commercialization partner for Pfenex and Adalvo, receives a positive opinion for PF708 from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
PF708 will be branded in Europe as Livogiva (teriparatide injection), a biosimilar product to the reference medicine Forsteo indicated for postmenopausal women with osteoporosis.
Additionally, Adalvo enters into a commercialization agreement with a large pharmaceutical company to commercialize PF708, upon receipt of marketing authorization, in certain in Latin American countries.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.